SCHEMBL3412935

SCHEMBL3412935

NNC(=O)c1ccccc1CO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.62
HPGD P15428 3/20 0.62
LMNA P02545 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
CTSD P07339 2/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
ALDH1A1 P00352 5/20 0.50
NPC1 O15118 1/20 0.50
TP53 P04637 1/20 0.50
RAB9A P51151 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
MITF O75030 1/20 0.47
NCOA1 Q15788 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
P2RX7 Q99572 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3135538 0.83 CTSD (0.56) GAAHPGDLMNAL3MBTL1CTSD
SCHEMBL1098843 0.83 GAA (0.62) GAAHPGDLMNAL3MBTL1CA1
SCHEMBL28801221 0.83 CTSD (0.52) GAAHPGDLMNAL3MBTL1CTSD
SCHEMBL5256509 0.82 HPGD (0.67) GAAHPGDLMNAL3MBTL1CA1
SCHEMBL239328 0.82 CTSD (0.63) GAACTSDCA1CA2CA9
SCHEMBL30547074 0.82 CTSD (0.63) GAACTSDCA1CA2CA9
SCHEMBL15129274 0.82 HPGD (0.61) GAAHPGDLMNAL3MBTL1ALDH1A1
SCHEMBL22596733 0.82 HPGD (0.61) GAAHPGDLMNAL3MBTL1ALDH1A1
SCHEMBL6868432 0.82 HPGD (0.66) GAAHPGDLMNAL3MBTL1CA1
SCHEMBL16772098 0.82 HPGD (0.61) GAAHPGDLMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104031037-B Formanilide compound containing 1, 3, 4-oxadiazole structure as well as preparation method and application thereof 南京工业大学 2017-01-18 CN disclosed
CN-104031037-A Formanilide compound containing 1,3, 4-oxadiazole structure as well as preparation method and application thereof NANJING UNIVERSITY OF TECHNOLOGY 2014-09-10 CN disclosed
EP-2260028-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2010-12-15 EP disclosed
WO-2009105214-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2009-08-27 WO disclosed
US-20090156509-A1 Tri-peptide Inhibitors of Serine Elastases ACCUTHERA, INC. (US) 2009-06-18 US disclosed
US-20080139560-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2008-06-12 US disclosed
US-20070281937-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2007-12-06 US disclosed
WO-2005097112-A2 ION CHANNEL MODULATORS WYETH (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281937-A1 Ion Channel Modulators CACNA1B, CACNA1C, TRPV1 GAA 1560/4885HPGD 2634/4885LMNA 1903/4885
US-20080139560-A1 Ion Channel Modulators CACNA1B, CACNA1C, TRPV1 GAA 1560/4885HPGD 2634/4885LMNA 1903/4885
US-20090156509-A1 Tri-peptide Inhibitors of Serine Elastases SCTR, CTRC, SERPINB1 GAA 2476/4885HPGD 2593/4885LMNA 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.